Monthly Archives: March 2015

UBS Reiterates a Hold Rating on ImmunoGen

In a report released today, Andrew Peters from UBS reiterated a Hold rating on ImmunoGen (NASDAQ: IMGN), with a price target of $9. The company’s shares opened today at $8.89. ImmunoGen has an analyst consensus of Hold, with a price

Analysts Weigh in on Auspex Pharmaceuticals Following Teva Acquisition

By Carly Forster Israeli bio-tech company Teva Pharmaceutical (NYSE: TEVA) announced on March 30th that it will acquire neurology drug company Auspex Pharmaceuticals (NASDAQ:  ASPX) for an equity value of $3.5 billion in an effort to expand its treatments for the

Piper Jaffray Maintains a Buy Rating on Ann Inc

In a report released today, Neely Tamminga from Piper Jaffray maintained a Buy rating on Ann Inc (NYSE: ANN), with a price target of $46. The company’s shares opened today at $41.17. Ann Inc has an analyst consensus of Hold,

Alcoa Inc. Receives a Hold from J.P. Morgan

J.P. Morgan analyst Michael Gambardella maintained a Hold rating on Alcoa Inc. (NYSE: AA) today and set a price target of $16.50. The company’s shares opened today at $12.82, close to its 52-week low of $12.25. Currently, the analyst consensus

Barclays Reiterates a Buy Rating on M/A-Com Technology

In a report released today, Blayne Curtis from Barclays reiterated a Buy rating on M/A-Com Technology (NASDAQ: MTSI), with a price target of $40. The company’s shares opened today at $37, close to its 52-week high of $39.52. M/A-Com Technology

Xilinx Receives Mixed Ratings Following Rumors of Altera Acquisition

By Sarah Roden Analysts are speculating about the future of Xilinx (NASDAQ: XLNX) ever since rumors of Intel (NASDAQ: INTC) buying Altera (NASDAQ: ALTR) surfaced. Xilinx, a leader in semiconductors and pioneer of the FPGA circuit, is a rival of